Herbs as old potential treatments for lymphedema management: A systematic review

Sheikhi-Mobarakeh, Zahra; Yarmohammadi, Hossein; Mokhatri-Hesari, Parisa; Fahimi, Shirin; Montazeri, Ali; Heydarirad, Ghazaleh

doi:10.1016/j.ctim.2020.102615

Cited by 9 publications

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Large families of medical herbs have emerged as promising avenues in the treatment of AD [ 234 , 235 , 236 , 237 , 238 , 239 , 240 , 241 , 242 , 243 , 244 , 245 , 246 , 247 , 248 , 249 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 266 , 267 , 268 , 269 , 270 , 271 , 272 , 273 , 274 ]. Although the mechanisms of their therapeutic action remain largely unknown, extensive studies have identified various beneficial compounds in their extracts, including flavonoids, alkaloids, tannins, triterpenes with anti-inflammatory, anti-amyloidogenic, anticholinesterase, and antioxidant effects.…”

Section: Discussionmentioning

confidence: 99%

Section: Natural Compounds As a Novel Treatment For Admentioning

confidence: 99%

“…Herbal medicine has been proposed as alternative method in reducing lymphedema burden and drainage of different tissues [ 262 , 263 ]. Indeed, coumarin, juniper, black pepper, geranium, sage, and fennel are known to reduce swelling, and French oak wood extract containing robuvit leads to a sharp reduction in swelling [ 262 ]. Particular effectiveness of plant flavonoids has been shown in filarial lymphedema (edema of infectious origin) and in patients with breast cancer (edema of tumor origin) [ 264 ].…”

Section: Natural Compounds As a Novel Treatment For Admentioning

confidence: 99%

See 2 more Smart Citations

Promising Strategies to Reduce the SARS-CoV-2 Amyloid Deposition in the Brain and Prevent COVID-19-Exacerbated Dementia and Alzheimer’s Disease

Navolokin,

Adushkina,

Zlatogorskaya

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by infection with the SARS-CoV-2 virus, is associated with cognitive impairment and Alzheimer’s disease (AD) progression. Once it enters the brain, the SARS-CoV-2 virus stimulates accumulation of amyloids in the brain that are highly toxic to neural cells. These amyloids may trigger neurological symptoms in COVID-19. The meningeal lymphatic vessels (MLVs) play an important role in removal of toxins and mediate viral drainage from the brain. MLVs are considered a promising target to prevent COVID-19-exacerbated dementia. However, there are limited methods for augmentation of MLV function. This review highlights new discoveries in the field of COVID-19-mediated amyloid accumulation in the brain associated with the neurological symptoms and the development of promising strategies to stimulate clearance of amyloids from the brain through lymphatic and other pathways. These strategies are based on innovative methods of treating brain dysfunction induced by COVID-19 infection, including the use of photobiomodulation, plasmalogens, and medicinal herbs, which offer hope for addressing the challenges posed by the SARS-CoV-2 virus.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Natural Compounds As a Novel Treatment For Admentioning

confidence: 99%

Section: Natural Compounds As a Novel Treatment For Admentioning

confidence: 99%

See 1 more Smart Citation

Promising Strategies to Reduce the SARS-CoV-2 Amyloid Deposition in the Brain and Prevent COVID-19-Exacerbated Dementia and Alzheimer’s Disease

Navolokin,

Adushkina,

Zlatogorskaya

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Other modalities for lymphedema management also have been investigated such as laser therapy or pneumatic compression pumps [44][45][46], but they have not been based on recent findings of lymphedema pathophysiology [47,48]. Only one included study in this systematic review had a question of pathophysiology (A) in the questionnaire [27], and this indicates the importance of more emphasis on the recent untranslated findings both in research and practice of lymphedema.…”

Section: Knowledge Of Lymphedemamentioning

confidence: 99%

Healthcare Practitioners’ Knowledge of Lymphedema

Yarmohammadi

Rooddehghan

Soltanipur

et al. 2021

International Journal of Vascular Medicine

Self Cite

View full text Add to dashboard Cite

Objectives. Lymphedema is neglected in medical education, and a review on healthcare practitioners’ (HCPs) knowledge is necessary to shed light on gaps and to provide evidence for establishing educational programs on lymphedema. Methods. This systematic review was performed based on the PRISMA guideline in PubMed, Scopus, Web of Science, and Google Scholar databases. There was no limitation on the type of lymphedema or HCPs. The quality assessment was performed based on QATSDD. Data regarding study characteristics, questionnaire context, and findings of the study were summarized from each article. Results. After the screening, 16 articles were included that 12 were cross-sectional, two were qualitative, and two were interventional pilot studies. Breast cancer and other cancer-related lymphedema, lymphatic filariasis, and podoconiosis were included, and the majority of articles were focused on primary HCPs. The overall knowledge was low and average in five and 11 articles, respectively, and prior education was a significant factor related to higher knowledge of lymphedema in two studies. Conclusion. Structured education of lymphedema is needed to increase the knowledge of HCPs and to enhance their collaboration in multidisciplinary care teams. Improvement of HCPs’ knowledge may lead to better outcomes of lymphedema patients’ management which are neglected.

show abstract

“…The mode of action of selenium is assumed to be mediated by immunomodulation. Available evidence suggests that various herbs are useful in alleviating lymphedema, but conclusive data showing superiority in the benefit/risk ratio of these products are missing [ 93 ].…”

Section: Lung Changes In Ardsmentioning

confidence: 99%

Acute Respiratory Distress Syndrome: Focus on Viral Origin and Role of Pulmonary Lymphatics

Frőhlich

2021

Biomedicines

View full text Add to dashboard Cite

Acute respiratory distress syndrome (ARDS) is a serious affection of the lung caused by a variety of pathologies. Great interest is currently focused on ARDS induced by viruses (pandemic influenza and corona viruses). The review describes pulmonary changes in ARDS and specific effects of the pandemic viruses in ARDS, and summarizes treatment options. Because the known pathogenic mechanisms cannot explain all aspects of the syndrome, the contribution of pulmonary lymphatics to the pathology is discussed. Organization and function of lymphatics in a healthy lung and in resorption of pulmonary edema are described. A future clinical trial may provide more insight into the role of hyaluronan in ARDS but the development of promising pharmacological treatments is unlikely because drugs play no important role in lymphedema therapy.

show abstract

Herbs as old potential treatments for lymphedema management: A systematic review

Cited by 9 publications

References 43 publications

Promising Strategies to Reduce the SARS-CoV-2 Amyloid Deposition in the Brain and Prevent COVID-19-Exacerbated Dementia and Alzheimer’s Disease

Promising Strategies to Reduce the SARS-CoV-2 Amyloid Deposition in the Brain and Prevent COVID-19-Exacerbated Dementia and Alzheimer’s Disease

Healthcare Practitioners’ Knowledge of Lymphedema

Acute Respiratory Distress Syndrome: Focus on Viral Origin and Role of Pulmonary Lymphatics

Contact Info

Product

Resources

About